pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
  1. pharmadog
  2. ›drugs
  3. ›Riluzole Rising
drug
save

riluzole

Marketedupdated 3mo ago
by Rising Pharma Holdings Inc
Approved
community read0 votes

🐶 often sniffed alongside

top 2
  • tagSmall Molecule2 co-mentions · 1 sources
  • tagDrug Shortage1 co-mentions · 1 sources

indications

investigational
ALS

all catalysts(0)

nothing on the calendar yet

Trials studying riluzole

  • phase3A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastomarecruitingn=2,250
  • phase2PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALSrecruitingn=105
  • phase1Pharmacokinetics of Y-4 Tablets With Pregabalin Capsules and Riluzole Tablets in U.S. Healthy Participantsnot yet recruitingn=11
  • phase3Long-term Safety Study of Adjunctive Troriluzole in Subjects With Obsessive Compulsive Disorderterminatedn=772
  • phase3Troriluzole (BHV-4157) in Adult Participants With Obsessive Compulsive Disordercompletedn=426
  • —Expanded Access Protocol of Troriluzole in Patients With Spinocerebellar Ataxia (SCA)available
  • phase3Efficacy and Safety Study of Adjunctive Troriluzole in Obsessive Compulsive Disordercompletedn=456
  • phase3Troriluzole in Adult Participants With Spinocerebellar Ataxiaactive not recruitingn=299
more trials →

Patent cliff

source: FDA Orange Book
first barrier falls
Mar 12, 2029
~2.6 years out

Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.

patents (1)

  • Mar 12, 2029formulationUS 87651502.6y

News(0)

no news has mentioned this drug yet

brand
Riluzole Rising
generic
riluzole
indication
Amyotrophic Lateral Sclerosis
phase
marketed
Data sources
ClinicalTrials.gov
last refreshed 10m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?